Department of Pathology, Yonsei University College of Medicine, Seoul 03722, Korea.
Int J Mol Sci. 2022 Oct 20;23(20):12578. doi: 10.3390/ijms232012578.
Thyroid cancer is the most common cancer in the endocrine system. Most thyroid cancers have good prognosis, but some of them are resistant to treatment or show aggressive behavior. Like other tumors, thyroid cancers harbor tumor microenvironment (TME) composed of cancer associated fibroblasts (CAF) and immune cells. Autoimmune lymphocytic thyroiditis can occur in the thyroid, and it may be associated with cancer development. TME is involved in tumor progression through various mechanisms: (1) CAF is involved in tumor progression through cell proliferation and extracellular matrix (ECM) remodeling; and (2) immune cells are involved in tumor progression through cell proliferation, angiogenesis, epithelial mesenchymal transformation (EMT), and immune suppression. These events are activated by various cytokines, chemokines, and metabolites secreted from cells that comprise TME. This review is focused on how CAF and immune cells, two important cell components of thyroid cancer TME, are involved in tumor progression, and will explore their potential as therapeutic targets.
甲状腺癌是内分泌系统最常见的癌症。大多数甲状腺癌预后良好,但有些则对治疗有抵抗力或表现出侵袭性行为。与其他肿瘤一样,甲状腺癌含有由癌相关成纤维细胞 (CAF) 和免疫细胞组成的肿瘤微环境 (TME)。自身免疫性淋巴细胞性甲状腺炎可发生于甲状腺,且可能与癌症的发生有关。TME 通过多种机制参与肿瘤进展:(1)CAF 通过细胞增殖和细胞外基质 (ECM) 重塑参与肿瘤进展;(2)免疫细胞通过细胞增殖、血管生成、上皮间质转化 (EMT) 和免疫抑制参与肿瘤进展。这些事件是由构成 TME 的细胞分泌的各种细胞因子、趋化因子和代谢物激活的。本综述重点介绍了甲状腺癌 TME 中两种重要的细胞成分 CAF 和免疫细胞如何参与肿瘤进展,并探讨了它们作为治疗靶点的潜力。